Quarterly report pursuant to Section 13 or 15(d)

Commitments and Contingencies (Details)

v3.23.1
Commitments and Contingencies (Details)
$ / shares in Units, $ in Millions
1 Months Ended 3 Months Ended 12 Months Ended 40 Months Ended 64 Months Ended
Oct. 31, 2022
USD ($)
Jul. 31, 2019
USD ($)
Sep. 30, 2018
USD ($)
therapy
milestone
Mar. 31, 2023
USD ($)
Mar. 31, 2020
USD ($)
milestone
Dec. 31, 2018
unit
$ / shares
Dec. 31, 2021
USD ($)
Dec. 31, 2023
USD ($)
Jun. 22, 2021
USD ($)
Jun. 09, 2021
USD ($)
May 28, 2021
USD ($)
Mar. 25, 2021
USD ($)
Feb. 03, 2020
USD ($)
Operating Leased Assets [Line Items]                          
Payment received   $ 2.0                      
Period after public launch to terminate agreement   3 years                      
Percentage of net present value of royalty payments   75.00%                      
Aevi                          
Operating Leased Assets [Line Items]                          
Milestone payment       $ 0.0                  
Aevi                          
Operating Leased Assets [Line Items]                          
Number of milestones | milestone         2                
Contingent consideration         $ 6.5                
Ichorion                          
Operating Leased Assets [Line Items]                          
Number of milestones | milestone     3                    
Contingent consideration     $ 15.0                    
Milestone payment       0.0                  
Milestone One | Aevi                          
Operating Leased Assets [Line Items]                          
Contingent consideration                         $ 2.0
Milestone One | Ichorion                          
Operating Leased Assets [Line Items]                          
Milestone payment             $ 6.0            
Milestone Two | Aevi                          
Operating Leased Assets [Line Items]                          
Contingent consideration                         $ 4.5
Milestone Two | Ichorion | Forecast                          
Operating Leased Assets [Line Items]                          
Milestone payment               $ 5.0          
Milestone Three | Ichorion                          
Operating Leased Assets [Line Items]                          
Milestone payment       0.0                  
Milestone Three | Ichorion | Forecast                          
Operating Leased Assets [Line Items]                          
Milestone payment               $ 4.0          
Kyowa Kirin Co., Ltd. (KKC) | AVTX-002 KKC License Agreement                          
Operating Leased Assets [Line Items]                          
Upfront license fee                       $ 10.0  
Percent of payments received from sublicensing                       30.00%  
Research and development expense       0.0                  
Cumulative expense recognized to date       0.0                  
Kyowa Kirin Co., Ltd. (KKC) | AVTX-002 KKC License Agreement | Milestone One                          
Operating Leased Assets [Line Items]                          
Maximum aggregate milestone payment                       $ 112.5  
Kyowa Kirin Co., Ltd. (KKC) | AVTX-002 KKC License Agreement | Milestone Two                          
Operating Leased Assets [Line Items]                          
Maximum aggregate milestone payment                       $ 75.0  
Astellas Pharma, Inc. (Astellas) | AVTX-006 Astellas License Agreement                          
Operating Leased Assets [Line Items]                          
Upfront license fee       0.5                  
Maximum aggregate milestone payment       5.5                  
Research and development expense       0.0                  
Cumulative expense recognized to date       0.5                  
Sanford Burnham Prebys Medical Discovery Institute | AVTX-008 Sanford Burnham Prebys License Agreement                          
Operating Leased Assets [Line Items]                          
Upfront license fee                 $ 0.4        
Research and development expense       0.0                  
Cumulative expense recognized to date       0.0                  
Patent costs                 0.5        
Sanford Burnham Prebys Medical Discovery Institute | AVTX-008 Sanford Burnham Prebys License Agreement | Milestone One                          
Operating Leased Assets [Line Items]                          
Maximum aggregate milestone payment                 24.2        
Sanford Burnham Prebys Medical Discovery Institute | AVTX-008 Sanford Burnham Prebys License Agreement | Milestone Two                          
Operating Leased Assets [Line Items]                          
Maximum aggregate milestone payment                 $ 50.0        
TRIS Pharma | Karbinal Agreement                          
Operating Leased Assets [Line Items]                          
Minimum quantity required | unit           70,000              
Make whole payment per unit (in dollars per share) | $ / shares           $ 30              
AVTX-002 PEAK Trial                          
Operating Leased Assets [Line Items]                          
Estimated employee incentive bonus $ 1.3                        
AVTX-301 Out-License | Alto                          
Operating Leased Assets [Line Items]                          
Maximum proceeds from milestones                     $ 18.6    
Revenue recognized from milestones to date       0.0                  
AVTX-406 License Assignment | ES                          
Operating Leased Assets [Line Items]                          
Revenue recognized from milestones to date       $ 0.0                  
AVTX-406 License Assignment | ES | Milestone One                          
Operating Leased Assets [Line Items]                          
Maximum proceeds from milestones                   $ 6.0      
AVTX-406 License Assignment | ES | Milestone Two                          
Operating Leased Assets [Line Items]                          
Maximum proceeds from milestones                   $ 20.0      
AVTX-801, AVTX-802, And AVTX-803 | Ichorion                          
Operating Leased Assets [Line Items]                          
Number of preclinical therapies | therapy     3                    
AVTX-913 | Ichorion                          
Operating Leased Assets [Line Items]                          
Number of preclinical therapies | therapy     1